Diagnostic delay in amyotrophic lateral sclerosis
European Journal of Neurology · 2023-09 · 30 (9) · 2595-2601
DOI: 10.1111/ene.15874 ↗At a glance
Übersichtsarbeit in European Journal of Neurology, published online on 2023-05-30. Written by Kelly G Gwathmey and 6 co-authors. Institution: Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, General Practitioners. Cited 78 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Department of Health, Cytokinetics.
Abstract (original language)
Background
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease, and the time from symptom onset to diagnosis remains long. With the advent of disease‐modifying treatments, the need to identify and diagnose ALS in a timely fashion has never been greater.
Methods
We reviewed the literature to define the severity of ALS diagnostic delay, the various factors that contribute to this delay (including patient and physician factors), and the role that site of symptom onset plays in a patient's diagnostic journey.
Results
Diagnostic delay is influenced by general practitioners’ lack of recognition of ALS due to disease rarity and heterogenous presentations. As a result, patients are referred to non‐neurologists, have unnecessary diagnostic testing, and may ultimately be misdiagnosed. Patient factors include their illness behavior—which impacts diagnostic delay—and their site of symptom onset. Limb‐onset patients have the greatest diagnostic delay because they are frequently misdiagnosed with degenerative spine disease or peripheral neuropathy.
Conclusion
Prompt ALS diagnosis results in more effective clinical management, with earlier access to disease‐modifying therapies, multidisciplinary care, and, if desired, clinical trial involvement. Due to lack of commercially available ALS biomarkers, alternative strategies to identify and triage patients who likely have ALS must be employed. Several diagnostic tools have been developed to encourage general practitioners to consider ALS and make an urgent referral to ALS specialists, bypassing unnecessary referrals to non‐neurologists and unnecessary diagnostic workup.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.
- CRMR SLA, CHU Tours, Tours, France.
- UMR1253 iBrain UMR, Université de Tours, INSERM, Tours, France.
- Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
ORCID profiles: Kelly G Gwathmey, Philippe Corcia, Chris J McDermott, Angela Genge, Stefan Sennfält, Mamede de Carvalho, Caroline Ingre
Funding
- Department of Health
- Cytokinetics
Cite
APA
Gwathmey, K. G., Corcia, P., McDermott, C. J., Genge, A., Sennfält, S., de Carvalho, M., & Ingre, C. (2023). Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology, 30(9), 2595-2601. https://doi.org/10.1111/ene.15874
Vancouver
Gwathmey KG, Corcia P, McDermott CJ, Genge A, Sennfält S, de Carvalho M, et al. Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology. 2023;30(9):2595-2601. doi:10.1111/ene.15874
BibTeX
@article{Gwathmey2023,
author = {Gwathmey, Kelly G and Corcia, Philippe and McDermott, Chris J and Genge, Angela and Sennfält, Stefan and de Carvalho, Mamede and Ingre, Caroline},
title = {Diagnostic delay in amyotrophic lateral sclerosis},
journal = {European Journal of Neurology},
year = {2023},
volume = {30},
number = {9},
pages = {2595--2601},
doi = {10.1111/ene.15874}
}
EUVIMED